{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T13:23:59Z","timestamp":1790342639426,"version":"4.1.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007052","name":"University of Verona","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007052","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ekir.2025.103742","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:19:21Z","timestamp":1766535561000},"page":"103742","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Dapagliflozin in Patients With CKD With Fabry Disease"],"prefix":"10.1016","volume":"11","author":[{"given":"Yuri","family":"Battaglia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Vitturi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Marchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Baciga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Caccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Gugelmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Loris","family":"Martinetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia Federica","family":"Stefanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Torresani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Pisani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Riccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Viazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Chimenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca Katiana","family":"Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livia","family":"Lenzini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Sechi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Zanoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Girelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Paolo","family":"Fadini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federico","family":"Nalesso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianni","family":"Carraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2025.103742_bib1","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.3390\/ijms19123726","article-title":"Mutations in the GLA gene and LysoGb3: is it really Anderson-Fabry disease?","volume":"19","author":"Duro","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ekir.2025.103742_bib2","doi-asserted-by":"crossref","DOI":"10.1080\/0886022X.2025.2454295","article-title":"Expanded screening for Fabry disease in patients with chronic kidney disease not on dialysis: a multicenter Italian experience","volume":"47","author":"Battaglia","year":"2025","journal-title":"Ren Fail"},{"key":"10.1016\/j.ekir.2025.103742_bib3","article-title":"Deficiency in the screening process of Fabry disease: analysis of chronic kidney patients not on dialysis","volume":"8","author":"Battaglia","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.ekir.2025.103742_bib4","doi-asserted-by":"crossref","first-page":"126","DOI":"10.5414\/CN109501","article-title":"Identification of new \u03b1-galactosidase A mutation responsible for Fabry disease: a case report","volume":"91","author":"Battaglia","year":"2019","journal-title":"Clin Nephrol"},{"key":"10.1016\/j.ekir.2025.103742_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.105423","article-title":"Stroke and chronic kidney disease in Fabry disease","volume":"30","author":"Tapia","year":"2021","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"10.1016\/j.ekir.2025.103742_bib6","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.2215\/CJN.04340510","article-title":"Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry","volume":"5","author":"Wanner","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.103742_bib7","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1681\/ASN.2006121400","article-title":"Antiproteinuric therapy and Fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta","volume":"18","author":"Tahir","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.103742_bib8","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s40265-019-01090-4","article-title":"Migalastat: a review in Fabry disease","volume":"79","author":"McCafferty","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ekir.2025.103742_bib9","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.3390\/genes13101751","article-title":"Biomarkers for monitoring renal damage due to Fabry disease in patients treated with migalastat: a review for nephrologists","volume":"13","author":"Jaurretche","year":"2022","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.ekir.2025.103742_bib46","article-title":"[ACEi and ARBs: proteinuria containment and nephroprotection]","volume":"41","author":"Aucella","year":"2024","journal-title":"G Ital Nefrol"},{"key":"10.1016\/j.ekir.2025.103742_bib10","doi-asserted-by":"crossref","DOI":"10.1093\/ckj\/sfae396","article-title":"Efficacy and safety of dapagliflozin in patients with CKD: real-world experience in 93 Italian renal clinics","volume":"18","author":"Minutolo","year":"2025","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2025.103742_bib11","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.103742_bib12","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2025.103742_bib13","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2025.103742_bib14","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/imj.16603","article-title":"Sodium-glucose cotransporter 2 inhibitors reduce albuminuria in patients with Fabry disease: a real-world case series","volume":"55","author":"Tsatsaronis","year":"2025","journal-title":"Intern Med J"},{"key":"10.1016\/j.ekir.2025.103742_bib15","article-title":"Real-world clinical outcomes in adult patients with Fabry disease: a 20-year retrospective observational cohort study from a single centre","volume":"43","author":"McCarron","year":"2025","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.ekir.2025.103742_bib16","doi-asserted-by":"crossref","first-page":"624","DOI":"10.3390\/biomedicines13030624","article-title":"Fabry disease: insights into pathophysiology and novel therapeutic strategies","volume":"13","author":"Thompson","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.ekir.2025.103742_bib17","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.3390\/jcm12113689","article-title":"Dapaglifozin on albuminuria in chronic kidney disease patients with Fabry disease: the DEFY study design and protocol","volume":"12","author":"Battaglia","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.ekir.2025.103742_bib18","series-title":"Recurrent urinary tract infections","year":"2025"},{"key":"10.1016\/j.ekir.2025.103742_bib19","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/ndt\/gfad164","article-title":"Interpretation of GFR slope in untreated and treated adult Fabry patients","volume":"39","author":"Pisani","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.103742_bib20","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/ckj\/sfy108","article-title":"New insights from the application of the FAbry STabilization indEX in a large population of Fabry cases","volume":"12","author":"Mignani","year":"2018","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.ekir.2025.103742_bib21","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1093\/ndt\/gfu320","article-title":"Analysis of risk factors associated with renal function trajectory over time: a comparison of different statistical approaches","volume":"30","author":"Leffondre","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.103742_bib25","article-title":"Renoprotective effects of SGLT2 inhibitors in patients with Fabry disease","volume":"45","author":"Okamoto","year":"2025","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.ekir.2025.103742_bib29","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1681\/ASN.0000000000000117","article-title":"Change in albuminuria and GFR slope as joint surrogate end points for kidney failure: implications for Phase 2 clinical trials in CKD","volume":"34","author":"Heerspink","year":"2023","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2025.103742_bib30","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/dom.15030","article-title":"Change in albuminuria as a surrogate endpoint for cardiovascular and renal outcomes in patients with diabetes","volume":"25","author":"Palmer","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ekir.2025.103742_bib47","doi-asserted-by":"crossref","first-page":"10822","DOI":"10.3390\/ijms221910822","article-title":"Inflammation and oxidative stress in diabetic kidney disease: the targets for SGLT2 inhibitors and GLP-1 receptor agonists","volume":"22","author":"Winiarska","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ekir.2025.103742_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247234","article-title":"Protective effects of dapagliflozin against oxidative stress-induced cell injury in human proximal tubular cells","volume":"16","author":"Zaibi","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.ekir.2025.103742_bib32","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s40620-024-01934-7","article-title":"Oxidative stress and its role in Fabry disease","volume":"37","author":"Cacciapuoti","year":"2024","journal-title":"J Nephrol"},{"key":"10.1016\/j.ekir.2025.103742_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.107603","article-title":"Global reach of over 20 years of experience in the patient-centered Fabry Registry: advancement of Fabry disease expertise and dissemination of real-world evidence to the Fabry community","volume":"139","author":"Wanner","year":"2023","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.ekir.2025.103742_bib35","article-title":"Two decades of experience of the Fabry Outcome Survey provides further confirmation of the long-term effectiveness of agalsidase alfa enzyme replacement therapy","volume":"43","author":"Ramaswami","year":"2025","journal-title":"Mol Genet Metab Rep"},{"key":"10.1016\/j.ekir.2025.103742_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/jimd.12771","article-title":"Renal and multisystem effectiveness of 3.9 years of migalastat in a global real-world cohort: results from the followME Fabry Pathfinders registry","volume":"48","author":"Hughes","year":"2025","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.ekir.2025.103742_bib38","article-title":"Supportive care in adults with Fabry disease: low-cost interventions for high-value achievements","volume":"1","author":"Chesini","year":"2024","journal-title":"JIM"},{"key":"10.1016\/j.ekir.2025.103742_bib39","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","article-title":"SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control","volume":"17","author":"Cowie","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.ekir.2025.103742_bib40","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1161\/CIRCULATIONAHA.119.040514","article-title":"The serendipitous story of SGLT2 inhibitors in heart failure","volume":"139","author":"Verma","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.ekir.2025.103742_bib41","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/ndt\/gfx009","article-title":"Parapelvic cysts, a distinguishing feature of renal Fabry disease","volume":"33","author":"Pisani","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2025.103742_bib42","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/ehjci\/jeaa354","article-title":"Trabecular complexity as an early marker of cardiac involvement in Fabry disease","volume":"23","author":"Camporeale","year":"2022","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.ekir.2025.103742_bib43","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s40620-025-02253-1","article-title":"Physical performance and nutritional status in patients with Fabry disease: study design of an Italian multicenter cross-sectional study","volume":"38","author":"Battaglia","year":"2025","journal-title":"J Nephrol"},{"key":"10.1016\/j.ekir.2025.103742_bib44","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1159\/000540236","article-title":"How do physical activity and exercise affect Fabry disease? Exploring a new opportunity","volume":"49","author":"Baciga","year":"2024","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.ekir.2025.103742_bib45","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s40620-024-02049-9","article-title":"Physical activity and exercise in chronic kidney disease: consensus statements from the Physical Exercise Working Group of the Italian Society of Nephrology","volume":"37","author":"Battaglia","year":"2024","journal-title":"J Nephrol"},{"key":"10.1016\/j.ekir.2025.103742_bib48","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1159\/000502547","article-title":"On behalf of the Italian Kidney Foundation \u201cFIR-Onlus\u201d. Evaluation of hypertension, proteinuria, and abnormalities of body weight in Italian adolescents participating in the world kidney days","volume":"45","author":"Battaglia","year":"2020","journal-title":"Kidney Blood Press Res"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925007600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024925007600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T05:40:06Z","timestamp":1773121206000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024925007600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2468024925007600"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2025.103742","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dapagliflozin in Patients With CKD With Fabry Disease","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2025.103742","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103742"}}